Search results
Results from the WOW.Com Content Network
There are targeted therapies for lung cancer, colorectal cancer, head and neck cancer, breast cancer, multiple myeloma, lymphoma, prostate cancer, melanoma and other cancers. [ 1 ] [ 4 ] [ 5 ] Biomarkers are usually required to aid the selection of patients who will likely respond to a given targeted therapy.
Radiation therapy is used to kill cancer cells; however, normal cells are also damaged in the process. Currently, therapeutic doses of radiation can be targeted to tumors with great accuracy using linear accelerators in radiation oncology; however, when irradiating using external beam radiotherapy, the beam will always need to travel through healthy tissue, and the normal liver tissue is very ...
Transarterial bland embolization (TAE, also known as HAE) is a catheter-based tumor treatment of the liver.In this procedure, embolizing agents (e.g., polyvinyl alcohol, gelfoam, acrylic copolymer gelatin particles, embospheres) can be delivered through the tumor's feeding artery in order to completely occlude the tumor's blood supply.
TACE of liver tumors derives its beneficial effect by two primary mechanisms. [3] Most tumors within the liver are supplied by the proper hepatic artery, so arterial embolization preferentially interrupts the tumor's blood supply and stalls growth until neovascularization. Secondly, focused administration of chemotherapy allows for delivery of ...
A new treatment for liver cancer which isolates the organ and “bathes” it in chemotherapy has been found to be effective in almost 90% of patients. ... to normal within days and maintaining an ...
In medicine, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer.The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth; hence in minimal entry, exit, or scattered radiation dose to healthy ...
1990s – RFA for soft tissue tumors, i.e., bone, breast, kidney, lung and liver cancer. 1997 – Intra-arterial delivery of tumor-killing viruses and gene therapy vectors to the liver. 1997 – HIFU first used to treat prostate cancer. 2012 – Pioneering liver chemoperfusion study reported by Delcath for disseminated liver metastases. [32]
Barcelona Clinic Liver Cancer (BCLC) Staging System. The prognosis of HCC is affected by the staging of the tumor, the liver's function due to the effects of chronic liver disease and cirrhosis as well as the person's physical performance status. [48] A number of staging classifications for HCC are available.